<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8006933</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4649</journal-id>
<journal-id journal-id-type="nlm-ta">J Dev Behav Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">J Dev Behav Pediatr</journal-id>
<journal-title-group>
<journal-title>Journal of developmental and behavioral pediatrics : JDBP</journal-title>
</journal-title-group>
<issn pub-type="ppub">0196-206X</issn>
<issn pub-type="epub">1536-7312</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27560971</article-id>
<article-id pub-id-type="pmc">5039060</article-id>
<article-id pub-id-type="doi">10.1097/DBP.0000000000000334</article-id>
<article-id pub-id-type="manuscript">NIHMS791829</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children with Fragile X Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hess</surname>
<given-names>Laura Greiss</given-names>
</name>
<degrees>PhD, OTR/L</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fitzpatrick</surname>
<given-names>Sarah E.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nguyen</surname>
<given-names>Danh V.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Yanjun</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaul</surname>
<given-names>Kimberly N.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schneider</surname>
<given-names>Andrea</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chitwood</surname>
<given-names>Kerrie Lemons</given-names>
</name>
<degrees>PhD, CCC-SLP</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eldeeb</surname>
<given-names>Marwa Abd Al Azaim</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Polussa</surname>
<given-names>Jonathan</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hessl</surname>
<given-names>David</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivera</surname>
<given-names>Susan</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="A2"><label>2</label>Department of Occupational Therapy, Dominican University of California, San Rafael, California, USA</aff>
<aff id="A3"><label>3</label>Department of Neuroscience, The Ohio State University, Columbus, Ohio, USA</aff>
<aff id="A4"><label>4</label>Department of Medicine, University of California, Irvine School of Medicine, Orange, California, USA</aff>
<aff id="A5"><label>5</label>Institute for Clinical and Translational Science, University of California, Irvine, California, USA</aff>
<aff id="A6"><label>6</label>Department of Psychology, University of California, Davis, Davis, California, USA</aff>
<aff id="A7"><label>7</label>Department of Pediatrics, University of California, Davis Medical Center, Sacramento, California, USA</aff>
<aff id="A8"><label>8</label>Department of Special Education, California State University, Monterey Bay</aff>
<aff id="A9"><label>9</label>Department of Psychiatry and Behavioral Sciences, University of California, Davis School of Medicine, Sacramento, California, USA</aff>
<author-notes>
<corresp id="cor1"><bold>Corresponding Author: Randi Hagerman, MD</bold>, <email>rjhagerman@ucdavis.edu</email>, MIND Institute, University of California Davis Medical Center, 2825 50<sup>th</sup> Street, Sacramento, CA 95817, Tel: (916) 703-0247, Fax: (916) 703-0240</corresp>
<fn fn-type="equal" id="FN1">
<label>*</label>
<p id="P1">These authors contributed equally to this study</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>22</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>37</volume>
<issue>8</issue>
<fpage>619</fpage>
<lpage>628</lpage>
<!--elocation-id from pubmed: 10.1097/DBP.0000000000000334-->
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P2">Observational studies and anecdotal reports suggest sertraline, a selective serotonin reuptake inhibitor (SSRI), may improve language development in young children with fragile X syndrome (FXS). We evaluated the efficacy of six months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS ages 2–6 years.</p>
</sec>
<sec id="S2">
<title>Results</title>
<p id="P3">Eighty-one subjects were screened for eligibility and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and three from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language age equivalent and Clinical Global Impression-Improvement (CGI-I). However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred.</p>
</sec>
<sec id="S3">
<title>Conclusion</title>
<p id="P4">This randomized controlled trial of six-months of sertraline treatment showed no primary benefit with respect to early expressive language development and global clinical improvement. However, in secondary, exploratory analyses there were significant improvements seen on motor and visual perceptual subtests, the Cognitive T score sum on the MSEL, and on one measure of Social Participation on the Sensory Processing Measure–Preschool. Further, post hoc analysis found significant improvement in early expressive language development as measured by the MSEL among children with ASD on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but we do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures, as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>